A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo

ConditionVitiligo
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12+
SponsorPeking University Third Hospital

About this trial

Vitiligo is a common chronic autoimmune skin disease that can occur on any part of the body and severely impacts patients' quality of life. Current treatment for vitiligo primarily include topical medications, phototherapy, systemic therapy and surgical interventions, but their efficacy is limited, often failing to achieve ideal therapeutic outcomes, and are associated with a high recurrence rate. This study is an investigator-initiated real-world research on the application of ruxolitinib cream for vitiligo treatment, with the primary objective of exploring the factors influencing the efficacy of ruxolitinib cream in treating vitiligo.

Eligibility criteria

Qualifiers

Age12 years or older, any gender;

Signed"Informed Consent Form";

Clinically diagnosed with non-segmental vitiligo;

Vitiligo area less than 10% of body surface area;

Disqualifiers

Allergy to ruxolitinib cream;

Pregnant or lactating women;

Any condition deemed inappropriate for study participation by the investigator.

Trial design

Treatments tested in this trial

  • Ruxolitinib 1.5% Cream BID

Treatment groups

170 Participants
are divided into 1 treatment group